Consensus Viatris Inc.

Equities

VTRS

US92556V1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.57 ^USD	+0.87%		+2.84%	+6.83%

Apr. 18	Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	MT
Apr. 18	UK Regulator to Consider Undertakings for Theramex-Viatris Deal	MT

Evolution of the average Target Price on Viatris Inc.

Price target over the last 5 years

History of analyst recommendation changes

ebec4f96e58a87.DZ5VvNLVqBHsCX7PPmdDcyBWzU7OYvZMFOINsNn8eMs.W8gi74Ke5FaDPyuIUB8cBBA3tDygEZIbVaVdneu3QJ1H2SeEvKXGZIVkFQ~a898ece0e1bc62cd7fc3070b59bef42d

Analyst Recommendations on Viatris Inc.

Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order	Apr. 14	MT
Stonex Group Insider Sold Shares Worth $488,142, According to a Recent SEC Filing	Mar. 25	MT
India's Nifty 50 set to open at new record high, buoyed by strong growth data	Nov. 30	RE
Piper Sandler Adjusts Viatris' Price Target to $11 From $10, Maintains Neutral Rating	Nov. 22	MT
Another clue on monetary policy?	Nov. 08
BofA Securities Downgrades Viatris to Underperform From Neutral, Adjusts Price Target to $9 From $13	23-10-23	MT
UBS Adjusts Viatris Price Target to $11 From $12, Maintains Neutral Rating	23-10-20	MT
Out with the old	23-10-02
Inflation, Interest-Rate Prospects Lift Wall Street Pre-Bell; Asia, Europe Off	23-08-07	MT
Barclays Downgrades Viatris to Underweight From Equalweight, Price Target is $11	23-06-23	MT
Fitch Affirms IDR of Viatris at 'BBB'; Outlook Stable	23-04-26	AQ
Barclays Downgrades Viatris to Equal Weight From Overweight, $11 Price Target	23-04-24	MT
Barclays Adjusts Price Target on Viatris to $16 From $15, Keeps Overweight Rating	23-02-28	MT
BMO Capital Downgrades Viatris to Market Perform From Outperform, Adjusts Price Target to $14 From $16	23-02-17	MT
Barclays Adjusts Price Target on Viatris to $15 From $16, Maintains Overweight Rating	23-02-01	MT
Jefferies Upgrades Viatris to Buy From Hold, Adjusts Price Target to $15 From $13	23-01-27	MT
Indian shares set for muted open ahead of GDP data	22-11-29	RE
UBS Upgrades Viatris to Neutral From Sell, Adjusts Price Target to $12 From $9	22-11-10	MT
Piper Sandler Upgrades Viatris to Neutral From Underweight, Price Target is $10	22-11-08	MT
Barclays Adjusts Viatris' Price Target to $16 From $21, Reiterates Overweight Rating	22-10-25	MT
Jefferies Starts Viatris at Hold With $11 Price Target	22-10-21	MT
BofA Securities Adjusts Viatris Price Target to $11 From $14, Maintains Neutral Rating	22-10-14	MT
BMO Capital Adjusts Viatris' Price Target to $16 From $19, Maintains Outperform Rating	22-08-09	MT
UBS Downgrades Viatris to Sell From Neutral, Adjusts Price Target to $9 From $12	22-06-14	MT
Piper Sandler Downgrades Viatris to Underweight From Neutral; Price Target is $10	22-05-10	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

11.47 USD

Average target price

12.4 USD

Spread / Average Target

+8.07%

High Price Target

14 USD

Spread / Highest target

+22.06%

Low Price Target

11 USD

Spread / Lowest Target

-4.10%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Viatris Inc.

Piper Sandler
BofA Securities
UBS
Barclays
BMO Capital
Jefferies & Co.
Citigroup
Raymond James
Truist Securities
JPMorgan Chase
Cowen
RBC Capital Markets
Goldman Sachs
J.P. Morgan Chase

Ratings for Viatris Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar